Rapid Identification of Pathogenic Bacteria and Sepsis Diagnosis

描述(申请人提供)：败血症是美国第十大死因和重症监护病房(ICU)第二大死因。脓毒症每年导致超过21.5万美国人死亡--比乳腺癌、肺癌和前列腺癌的总和还要多。快速鉴定和测定抗生素敏感性是有效治疗感染患者的关键。第一阶段成功地展示了iSense系统区分细菌物种和菌株的能力，速度比传统方法单独识别物种快4倍。在第一阶段，iSense还成功地证明了确定菌株对抗生素治疗的特定敏感性的能力比传统做法快1天以上。第二阶段的目的是解决临床人类样本的应用，以及开发适合商业使用的仪器和介质。这项研究的最终目标是开发并商业化部署一种自动化血液培养系统，该系统可以在实验室收到原始样本后不到24小时内诊断败血症，鉴定感染微生物的种类和菌株，并确定抗生素敏感性。

DESCRIPTION (provided by applicant): Sepsis is the tenth-leading cause of death in the United States and the second-leading cause of death in the intensive care unit (ICU). Sepsis kills over 215,000 Americans each year - more than breast cancer, lung cancer, and prostate cancer combined. Rapid identification and determination of antibiotic susceptibility is critical fo effective treatment of infected patients. Phase I successfully demonstrated the iSense system's ability to discriminate bacterial species and strain 4-fold faster than legacy methods identify species alone. In Phase I iSense also successfully demonstrated the ability to determine strain-specific susceptibility to antibiotic therapy more than 1 day faster than conventional practice. Phase II aims address application to clinical human specimens along with development of instruments and media appropriate for commercial use. The ultimate goal of this research is to develop and commercially deploy an automated blood culture system that can diagnose sepsis, identify the species and strain of the infecting organism, and determine antibiotic susceptibility all in less than 24 hours from the lab's receipt of primary specimen.